Stephen Holleran
Columbia University
23 Papers
75 Citations
Stephen Holleran is an academic researcher from Columbia University. The author has contributed to research in topics: Apolipoprotein B & Very low-density lipoprotein. The author has an hindex of 16, co-authored 23 publications. Previous affiliations of Stephen Holleran include Tufts University & Columbia University Medical Center.
Chat about Author
Papers
Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
Gissette Reyes-Soffer,Marianna Pavlyha,Colleen Ngai,Tiffany Thomas,Stephen Holleran,Rajasekhar Ramakrishnan,Wahida Karmally,Renu Nandakumar,Nelson Fontanez,Joseph C. Obunike,Santica M. Marcovina,Alice H. Lichtenstein,Nirupa R Matthan,James Matta,Magali Maroccia,Frederic Becue,Franck Poitiers,Brian Swanson,Lisa Cowan,William J. Sasiela,Howard K. Surks,Henry N. Ginsberg +21 more
TL;DR: Results are consistent with increases in LDL receptors available to clear IDL and LDL from blood during PCSK9 inhibition, and suggest that increased LDL receptors may also play a role in the reduction of plasma Lp(a) levels.
Hormonal Regulation of Lipoprotein(a) Levels: Effects of Estrogen Replacement Therapy on Lipoprotein(a) and Acute Phase Reactants in Postmenopausal Women
TL;DR: The lack of correlation between the changes in two acute phase reactants and Lp(a) suggests different underlying mechanisms for the effects of estrogen on these liver-derived proteins.
82
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects
John S. Millar,Gissette Reyes-Soffer,Patricia Jumes,Richard L. Dunbar,Emil M. deGoma,Amanda Baer,Wahida Karmally,Daniel S. Donovan,Hashmi Rafeek,Laura Pollan,Junichiro Tohyama,Amy O. Johnson-Levonas,John A. Wagner,Stephen Holleran,Joseph C. Obunike,Yang Liu,Rajasekhar Ramakrishnan,Michael E. Lassman,David E. Gutstein,Henry N. Ginsberg,Daniel J. Rader +20 more
TL;DR: It is indicated that anacetrapib, given alone or in combination with a statin, reduces LDL-ApoB-100 levels by increasing the rate of ApoB- 100 fractional clearance.
Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial
Gissette Reyes-Soffer,Colleen Ngai,Laura C. Lovato,Wahida Karmally,Rajasekhar Ramakrishnan,Stephen Holleran,Henry N. Ginsberg +6 more
TL;DR: FENO-S lowered PP TG similarly in all participants compared with PL-S, but levels of atherogenic apoB48 particles were reduced only in individuals with increased fasting levels of TG, which may have implications for interpretation of the overall ACCORD Lipid trial.
48
Immunization Data Exchange With Electronic Health Records.
Melissa S. Stockwell,Karthik Natarajan,Rajasekhar Ramakrishnan,Stephen Holleran,Kristen Forney,Angel Aponte,David K. Vawdrey +6 more
TL;DR: This study demonstrates that data exchange can improve child and adolescent immunization status and immunization record completeness and development of the technology to support such exchange and continued focus on local, state, and federal policies tosupport such exchanges are needed.
42